Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.

Levine RL, Valk PJM.

Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. No abstract available.

2.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL.

Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.

PMID:
30755419
3.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O, Ochi Y, Klement P, Chou WC, Blau IW, Tang JL, Zemojtel T, Shiraishi Y, Shiozawa Y, Thol F, Ganser A, Löwenberg B, Linch DC, Bullinger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F.

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

PMID:
30610028
4.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3. Epub 2018 Dec 12.

PMID:
30542144
5.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

6.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Löwenberg B, Valk PJM.

N Engl J Med. 2018 Jun 21;378(25):2443. doi: 10.1056/NEJMc1805501. No abstract available.

PMID:
29924951
7.

Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192.

8.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

9.

Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging.

Kallemeijn MJ, Kavelaars FG, van der Klift MY, Wolvers-Tettero ILM, Valk PJM, van Dongen JJM, Langerak AW.

Front Immunol. 2018 Mar 6;9:448. doi: 10.3389/fimmu.2018.00448. eCollection 2018.

10.

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.

Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Valk PJM, Visser O, Cornelissen JJ, Westerweel PE.

Eur J Haematol. 2018 Apr;100(4):367-371. doi: 10.1111/ejh.13023. Epub 2018 Feb 7.

PMID:
29288559
11.

No Effects of Successful Bidirectional SMR Feedback Training on Objective and Subjective Sleep in Healthy Subjects.

Binsch O, Wilschut ES, Arns M, Bottenheft C, Valk PJL, Vermetten EHGJM.

Appl Psychophysiol Biofeedback. 2018 Mar;43(1):37-47. doi: 10.1007/s10484-017-9384-y.

PMID:
29090400
12.

C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.

Marneth AE, Prange KHM, Al Hinai ASA, Bergevoet SM, Tesi N, Janssen-Megens EM, Kim B, Sharifi N, Yaspo ML, Kuster J, Sanders MA, Stoetman ECG, Knijnenburg J, Arentsen-Peters TCJM, Zwaan CM, Stunnenberg HG, van den Heuvel-Eibrink MM, Haferlach T, Fornerod M, Jansen JH, Valk PJM, van der Reijden BA, Martens JHA.

Leukemia. 2018 Mar;32(3):828-836. doi: 10.1038/leu.2017.280. Epub 2017 Sep 5.

PMID:
28871137
13.

Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.

Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Valk PJM, Visser O, Cornelissen JJ, Westerweel PE.

Haematologica. 2017 Dec;102(12):e486-e489. doi: 10.3324/haematol.2017.175265. Epub 2017 Aug 31. No abstract available.

14.

Recurrently affected genes in juvenile myelomonocytic leukaemia.

Obenauer JC, Kavelaars FG, Sanders MA, de Vries ACH, de Haas V, Beverloo HB, De Moerloose B, Lammens T, Dworzak M, Hoogenboezem RM, Valk PJM, Touw IP, van den Heuvel-Eibrink MM.

Br J Haematol. 2018 Jul;182(1):135-138. doi: 10.1111/bjh.14737. Epub 2017 May 9. No abstract available.

PMID:
28485469
15.

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME.

Cancer Discov. 2017 Aug;7(8):868-883. doi: 10.1158/2159-8290.CD-16-1032. Epub 2017 Apr 13.

16.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

17.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
18.

MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia.

Rauch PJ, Ellegast JM, Widmer CC, Fritsch K, Goede JS, Valk PJ, Löwenberg B, Takizawa H, Manz MG.

Blood. 2016 Nov 3;128(18):2253-2257. Epub 2016 Aug 29.

19.

MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice.

Alemdehy MF, de Looper HW, Kavelaars FG, Sanders MA, Hoogenboezem R, Löwenberg B, Valk PJ, Touw IP, Erkeland SJ.

Leukemia. 2016 Nov;30(11):2238-2241. doi: 10.1038/leu.2016.171. Epub 2016 Jun 4. No abstract available.

PMID:
27363282
20.

Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome.

Obenauer JC, Kavelaars FG, Sanders MA, Hoogenboezem RM, de Vries AC, van Strien PM, de Haas V, Locatelli F, Hasle H, Valk PJ, Touw IP, van den Heuvel-Eibrink MM.

Haematologica. 2016 Dec;101(12):e479-e481. Epub 2016 Sep 1. No abstract available.

21.

Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude.

Valk PJ, Simons R, Jetten AM, Valiente R, Labeaga L.

Aerosp Med Hum Perform. 2016 Jul;87(7):622-7. doi: 10.3357/AMHP.4522.2016.

PMID:
27503042
22.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ.

Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.

PMID:
27416910
23.

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, Tzankov A, Iacovino M, Lau IJ, Milne TA, Royo H, Kyba M, Valk PJM, Peters AHFM, Schwaller J.

Cancer Cell. 2016 Jul 11;30(1):43-58. doi: 10.1016/j.ccell.2016.05.011. Epub 2016 Jun 23.

24.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

25.

MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Yokoyama T, Nakatake M, Kuwata T, Couzinet A, Goitsuka R, Tsutsumi S, Aburatani H, Valk PJ, Delwel R, Nakamura T.

J Clin Invest. 2016 May 2;126(5):1664-78. doi: 10.1172/JCI81516. Epub 2016 Mar 28.

26.

A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.

Anguita E, Gupta R, Olariu V, Valk PJ, Peterson C, Delwel R, Enver T.

Dev Biol. 2016 Mar 15;411(2):277-286. doi: 10.1016/j.ydbio.2016.02.002. Epub 2016 Feb 3.

27.

Review: Aberrant EVI1 expression in acute myeloid leukaemia.

Hinai AA, Valk PJ.

Br J Haematol. 2016 Mar;172(6):870-8. doi: 10.1111/bjh.13898. Epub 2016 Jan 5. Review.

PMID:
26729571
28.

A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.

Niavarani A, Herold T, Reyal Y, Sauerland MC, Buchner T, Hiddemann W, Bohlander SK, Valk PJ, Bonnet D.

Br J Haematol. 2016 Feb;172(3):401-11. doi: 10.1111/bjh.13836. Epub 2015 Nov 24.

29.

Examining the Relationship Between Mental, Physical, and Organizational Factors Associated With Attrition During Maritime Forces Training.

Binsch O, Banko KM, Veenstra BJ, Valk PJ.

J Strength Cond Res. 2015 Nov;29 Suppl 11:S187-91. doi: 10.1519/JSC.0000000000001117.

PMID:
26506186
30.

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.

de Leeuw DC, Verhagen HJ, Denkers F, Kavelaars FG, Valk PJ, Schuurhuis GJ, Ossenkoppele GJ, Smit L.

Leukemia. 2016 Mar;30(3):742-6. doi: 10.1038/leu.2015.160. Epub 2015 Jun 25. No abstract available.

PMID:
26108690
31.

Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered.

Zeijlemaker W, Kelder A, Wouters R, Valk PJM, Witte BI, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.

Br J Haematol. 2015 Oct;171(2):227-238. doi: 10.1111/bjh.13572. Epub 2015 Jun 24.

PMID:
26104974
32.

Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.

Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP.

Ann Hematol. 2015 Jun;94(6):1079. doi: 10.1007/s00277-015-2356-5. No abstract available.

PMID:
25821085
33.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

34.

Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Boer JM, Koenders JE, van der Holt B, Exalto C, Sanders MA, Cornelissen JJ, Valk PJ, den Boer ML, Rijneveld AW.

Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13. No abstract available.

35.

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.

Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, Hakem A, Ibrahimova N, Arruda A, Löwenberg B, Valk PJ, Minden MD, Salmena L.

Leukemia. 2015 Jul;29(7):1485-95. doi: 10.1038/leu.2015.51. Epub 2015 Mar 4.

PMID:
25736236
36.

Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis.

Plompen EP, Valk PJ, Chu I, Darwish Murad SD, Plessier A, Turon F, Trebicka J, Primignani M, Garcia-Pagán JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie).

Haematologica. 2015 Jun;100(6):e226-8. doi: 10.3324/haematol.2014.120857. Epub 2015 Feb 14. No abstract available.

37.

RNA sequencing reveals a unique fusion of the lysine (K)-specific methyltransferase 2A and smooth muscle myosin heavy chain 11 in myelodysplastic syndrome and acute myeloid leukemia.

Sanders MA, Kavelaars FG, Zeilemaker A, Al Hinai AS, Abbas S, Beverloo HB, van Lom K, Valk PJ.

Haematologica. 2015 Jan;100(1):e1-3. doi: 10.3324/haematol.2014.110775. No abstract available.

38.

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.

Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP.

Ann Hematol. 2015 May;94(5):879-80. doi: 10.1007/s00277-014-2272-0. Epub 2014 Dec 11. No abstract available. Erratum in: Ann Hematol. 2015 Jun;94(6):1079. Kavelaars, François F [corrected to Kavelaars, François G].

PMID:
25491280
39.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
40.

Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Döhner H, Löwenberg B, Döhner K, Delwel R, Valk PJ.

Blood. 2015 Jan 1;125(1):133-9. doi: 10.1182/blood-2014-07-591461. Epub 2014 Nov 7.

41.

NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

Xue L, Pulikkan JA, Valk PJ, Castilla LH.

Blood. 2014 Jul 17;124(3):426-36. doi: 10.1182/blood-2013-12-541730. Epub 2014 Jun 3.

42.

A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R.

Cell. 2014 Apr 10;157(2):369-381. doi: 10.1016/j.cell.2014.02.019. Epub 2014 Apr 3.

43.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E, Hoogenboezem R, Reinders MJ, Figueroa ME, Valk PJ, Löwenberg B, Melnick A, Delwel R.

Blood. 2014 May 22;123(21):3327-35. doi: 10.1182/blood-2013-07-512855. Epub 2014 Mar 25.

44.

PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.

Zhou J, Wu J, Li B, Liu D, Yu J, Yan X, Zheng S, Wang J, Zhang L, Zhang L, He F, Li Q, Chen A, Zhang Y, Zhao X, Guan Y, Zhao X, Yan J, Ni J, Nobrega MA, Löwenberg B, Delwel R, Valk PJ, Kumar A, Xie L, Tenen DG, Huang G, Wang QF.

Leukemia. 2014 Jul;28(7):1436-48. doi: 10.1038/leu.2013.384. Epub 2013 Dec 26.

45.

Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.

Abbas S, Sanders MA, Zeilemaker A, Geertsma-Kleinekoort WM, Koenders JE, Kavelaars FG, Abbas ZG, Mahamoud S, Chu IW, Hoogenboezem R, Peeters JK, van Drunen E, van Galen J, Beverloo HB, Löwenberg B, Valk PJ.

Haematologica. 2014 May;99(5):848-57. doi: 10.3324/haematol.2013.095604. Epub 2014 Jan 17.

46.

Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.

Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, Lefebvre V, Valk PJ, Delwel R, Hoogenkamp M, Nerlov C, Cammenga J, Saez B, Scadden DT, Bonifer C, Ye M, Tenen DG.

Cancer Cell. 2013 Nov 11;24(5):575-88. doi: 10.1016/j.ccr.2013.09.018. Epub 2013 Oct 31. Erratum in: Cancer Cell. 2014 Feb 10;25(2):257. Diruscio, Annalisa [corrected to Di Ruscio, Annalisa].

47.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
48.

The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL.

Humbert M, Federzoni EA, Britschgi A, Schläfli AM, Valk PJ, Kaufmann T, Haferlach T, Behre G, Simon HU, Torbett BE, Fey MF, Tschan MP.

J Leukoc Biol. 2014 Jan;95(1):83-93. doi: 10.1189/jlb.1112608. Epub 2013 Sep 13.

49.

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.

Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, Zhang SD, Chng WJ, Hong CW, Mills K, Zeng Q.

EMBO Mol Med. 2013 Sep;5(9):1351-66. doi: 10.1002/emmm.201202183. Epub 2013 Aug 8.

50.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkoppele GJ, Janssen JJ.

Eur J Cancer. 2013 Oct;49(15):3242-6. doi: 10.1016/j.ejca.2013.06.018. Epub 2013 Jul 19.

Supplemental Content

Support Center